eOn Communications Skyrockets on Inventergy's Inked Agreement (NASDAQ:EONC), Origin Agritech Ltd. (NASDAQ:SEED), Oxygen Biotherapeutics (NASDAQ:OXBT)

With financial revenue, sales, and performance outlooks firmly placed on traders minds, we would advise you to take a look at eOn Communications Corporation ticker symbol (NASDAQ:EONC). eOn Communications Corporation has surged +32.38% Up 0.90 generating over one point four million shares in the financial market at $3.68 per share Monday January 6, 2014 Real-time: 11:53AM EST. The Company (www.eoncc.com) is a global provider of innovative communications solutions. The topic of interest amongst investors surrounding eOn Communications Corporation is its reverse merger of Inventergy as a amalgamate entity obtaining a ratio of 500 mobile 3G and 4G patents from an inked agreement with Panasonic Corporation.

This move increases the Inventergy’s portfolio to greater than 660 patents. As eOn Communications Corporation and Inventergy becomes Inventergy Global expect this Company to become a major player in the telecommunications sector in the future.

On a different note, take a look at Origin Agritech Limited ticker symbol(NASDAQ:SEED). Origin Agritech Limited has surged +31.04% Up 0.57 generating over five point three million shares in the financial market at $2.41 per share Monday January 6, 2014 Real-time: 12:24PM EST. The Company (www.originseed.com.cn) is a technology-focused supplier of crop seeds in China. The topic of interest amongst investors surrounding Origin Agritech Limited is its upcoming FY 2013 results expected January 8, 2014.

Another ticker symbol that absolutely need to be mentioned is (NASDAQ:OXBT). Oxygen Biotherapeutics, Inc. has surged +30.25% Up 1.44 generating over five point four million shares in the financial market at $6.20 per share Monday January 6, 2014 Real-time: 12:29PM EST. The Company (www.oxybiomed.com) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The topic of interest amongst investors surrounding Oxygen Biotherapeutics, Inc. is its key details of phase 3 trial protocol for Levosimendan. Levosimendan is a calcium sensitizer developed for intra-venous use in hospitalized patients with acutely decompensated heart failure. The global cardiovascular therapeutic drug market is expected to reach US$139.8 billion by 2015.

Read Full Disclaimer at http://crweselect.com/disclaimer/

Remember: Always do your homework and consult your own financial professional.